Why WHO Is Testing Ervebo Instead of Rolling It Out Widely for Bundibugyo Ebola

The World Health Organization’s approach to Ervebo in the 2026 Bundibugyo Ebola outbreak is a cautious attempt to protect people and establish whether the vaccine works against the virus actually driving the outbreak.

Ervebo is a licensed vaccine for Ebola disease caused by Zaire ebolavirus. The outbreak in the Democratic Republic of the Congo and Uganda is caused by Bundibugyo virus, a distinct Ebola virus species. WHO says available laboratory, animal, immunological and observational findings suggest Ervebo may offer cross-protection, but the evidence is insufficient to determine whether it provides clinically meaningful protection in humans. 20

That is why WHO has not recommended a blanket, programmatic community rollout. Instead, it has paired targeted vaccination of people at high occupational risk with a Phase 3 trial designed to produce the evidence needed for future policy.

The central issue: a licensed vaccine is not automatically proven for every Ebola virus

Ervebo’s approval and previous use concern Ebola virus disease caused by Zaire ebolavirus, not Bundibugyo virus disease. WHO’s emergency guidance does not dismiss the possibility of protection against Bundibugyo; it says that human protection remains unknown despite suggestive early evidence. 2021

This distinction matters in an outbreak response. A broad campaign implies that a vaccine has a known, meaningful protective effect in the target population. Without that evidence, public-health authorities cannot reliably estimate how much disease a campaign would prevent, how to prioritize doses, or whether changes in transmission are attributable to vaccination rather than other response measures.

Why run a Phase 3 trial during the outbreak?

The 70,000-dose allocation is deliberately split between immediate risk reduction and evidence generation. WHO and Africa CDC said that 20,000 doses were allocated to a Phase 3 clinical trial examining Ervebo’s impact against Bundibugyo virus, while 50,000 doses were designated for frontline and health workers under WHO SAGE recommendations. 22

A controlled trial can answer the question that laboratory and animal studies cannot: whether vaccination reduces Bundibugyo disease in people under real outbreak conditions. Its findings can also inform future decisions on the vaccine’s safety, delivery and potential role in outbreaks caused by this virus.

The alternative—unstructured, widespread use—could expend a limited supply without yielding a clear answer about effectiveness. In an emergency, uncertainty is not resolved simply by using more doses; it requires evidence that can distinguish a vaccine effect from the effects of changing exposure, case detection and infection-control measures.

Why vaccinate frontline and health workers now?

Targeted use for frontline and health workers reflects a different risk-benefit calculation from mass vaccination. Health workers face direct occupational exposure, and WHO documented continued infections among this group during the outbreak. As of 9 August, at least 155 health-worker cases and 45 deaths had been reported. 17

For workers with especially high exposure, the possibility of cross-protection may justify access to Ervebo even though efficacy against Bundibugyo has not been proven. That precautionary use should not be confused with confirmation that the vaccine protects the wider community against Bundibugyo virus.

WHO reported that vaccination of health-care workers with Ervebo began in the Democratic Republic of the Congo on 27 August. 5

No licensed Bundibugyo-specific vaccine or treatment yet

WHO says there is no vaccine or specific treatment established for Bundibugyo virus disease, although candidate interventions are being evaluated. 6

Two Bundibugyo-targeted vaccines had entered human trials by mid-August, according to WHO. 25 Those studies are important, but early-stage trials do not provide an immediately deployable, proven population vaccine for an active outbreak.

Treatment research is proceeding separately. The PARTNERS trial in the Democratic Republic of the Congo is evaluating whether the monoclonal antibody MBP134 and the antiviral remdesivir, alone or in combination, can improve survival in people diagnosed with Bundibugyo virus disease. 30 These are research candidates, not established treatments; testing them rigorously is essential before their benefits can be assumed.

Containment cannot wait for vaccine results

Vaccines and therapeutics are only parts of the response. WHO’s operational support emphasizes surveillance, contact tracing, clinical preparedness and management, supplies, community engagement and cross-border preparedness. 6

These measures remain crucial because they do not depend on uncertain cross-protection. Finding cases quickly, caring for patients safely, tracing contacts, strengthening infection prevention and control, and supporting safe, dignified burials are core tools for interrupting transmission.

The stakes are high. WHO reported 5,794 confirmed cases and 2,786 deaths in the Democratic Republic of the Congo as of 26 August, a crude case-fatality ratio of 48.1%. 5 Those figures underscore why the response cannot rely on an unproven vaccine effect—nor delay proven outbreak-control measures while trials proceed.

The practical takeaway

WHO’s policy is not a choice between action and research. It is a dual strategy:

• Offer Ervebo to frontline and health workers, whose exposure risk is especially high.
• Use a Phase 3 trial to determine whether the Zaire-targeted vaccine provides meaningful protection against Bundibugyo virus in humans.
• Continue proven containment measures while vaccines and treatments are assessed.

That approach preserves the possibility that Ervebo could help in this outbreak while avoiding a claim the evidence does not yet support: that a vaccine proven for Zaire ebolavirus is already proven to prevent Bundibugyo Ebola disease. 2022